Navigation Links
Prostate cancer biomarkers identified in seminal fluid
Date:6/6/2014

Improved diagnosis and management of one of the most common cancers in men prostate cancer could result from research at the University of Adelaide, which has discovered that seminal fluid (semen) contains biomarkers for the disease.

Results of a study now published in the journal Endocrine-Related Cancer have shown that the presence of certain molecules in seminal fluid indicates not only whether a man has prostate cancer, but also the severity of the cancer.

Speaking in the lead-up to Men's Health Week (9-15 June), University of Adelaide research fellow and lead author Dr Luke Selth says the commonly used PSA (prostate specific antigen) test is by itself not ideal to test for the cancer.

"While the PSA test is very sensitive, it is not highly specific for prostate cancer," Dr Selth says. "This results in many unnecessary biopsies of non-malignant disease. More problematically, PSA testing has resulted in substantial over-diagnosis and over-treatment of slow growing, non-lethal prostate cancers that could have been safely left alone.

"Biomarkers that can accurately detect prostate cancer at an early stage and identify aggressive tumors are urgently needed to improve patient care. Identification of such biomarkers is a major focus of our research," he says.

Dr Selth, a Young Investigator of the Prostate Cancer Foundation (USA), is a member of the Freemasons Foundation Centre for Men's Health at the University of Adelaide and is based in the University's Dame Roma Mitchell Cancer Research Laboratories.

Using samples from 60 men, Dr Selth and colleagues discovered a number of small ribonucleic acid (RNA) molecules called microRNAs in seminal fluid that are known to be increased in prostate tumors. The study showed that some of these microRNAs were surprisingly accurate in detecting cancer.

"The presence of these microRNAs enabled us to more accurately discriminate between patients who had cancer and those who didn't, compared with a standard PSA test," Dr Selth says. "We also found that the one specific microRNA, miR-200b, could distinguish between men with low grade and higher grade tumors. This is important because, as a potential prognostic tool, it will help to indicate the urgency and type of treatment required."

This research builds on previous work by Dr Selth's team, published in the British Journal of Cancer, which demonstrated that microRNAs in the blood can predict men who are likely to relapse after surgical removal of their prostate cancer. "We are excited by the potential clinical application of microRNAs in a range of body fluids," he says.


'/>"/>

Contact: Dr. Luke Selth
luke.selth@adelaide.edu.au
61-882-223-618
University of Adelaide
Source:Eurekalert

Related biology news :

1. Circumcision linked to reduced risk of prostate cancer in some men
2. Prostate cancer and blood lipids share genetic links
3. Circumcision could prevent prostate cancer... if its performed after the age of 35
4. A gene family that suppresses prostate cancer
5. CNIO researcher awarded by the Prostate Cancer Foundation
6. Cholesterol study suggests new diagnostic, treatment approach for prostate cancer
7. Targeting metabolism to develop new prostate cancer treatments
8. Myriads Prolaris significantly modifies treatment decisions for prostate cancer patients
9. Mechanism affecting risk of prostate cancer is found
10. Genetic mutation may play key role in risk of lethal prostate cancer in overweight patients
11. Men with prostate cancer who ate a low-fat fish oil diet showed changes in their cancer tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... ... March 29, 2017 , ... ComplianceOnline, the leading governance, risk ... its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. The Summit will ... in Boston, MA. , The Omni Parker House Hotel, which is located at 60 ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, ... oncology and drug-delivery therapies, today announced that an ... and Drug Administration voted 11 to 0 that ... skin) injection was favorable for patients in the ... lymphoma and chronic lymphocytic leukemia. The FDA action ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, a privately owned ... travel award to noteworthy scientists who will be presenting research using ACEA Biosciences’ ... of awards are being given to two postdoctoral fellows studying pathogen capture by ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a company developing natural products ... through enhancement of the gut microbiota, today announced the closing of its first round ... York-based Sustainable Income Capital Management, LLC and a number of private investors. The company ...
Breaking Biology Technology: